FindTrial
Sign In

Expression of defensin related proteins in cancers of head and neck

Beta defensin expression in malignant head and neck tumors.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026066
Enrollment
40
Registered
2020-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx Health Condition 2: C00-D49- Neoplasms

Interventions

Intervention1: Human B defensin expression: 300 mg of the tissue will be harvested in liquid nitrogenous and stored at -70 degree till the processing mRNA will be isolated by kit method mRNA will b

Sponsors

AIIMS Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of head and neck cancers during the study period

Exclusion criteria

Exclusion criteria: Patients with known mutation diagnosed tumour syndromes of pre confirmed familial cancer syndromes will be excluded as their molecular progression is already established. Patients not consenting for the study will also be excluded.

Design outcomes

Primary

MeasureTime frame
Expression of Human Beta defensin 1 and expression of human beta defensin 3Timepoint: 1st year 15 TO 20 cases 2nd year 15 TO 20 cases—

Secondary

MeasureTime frame
relative expression of HBD1 and HBD3 AND CORRELATION OF RATIO OF hbd EXPRESSION TO THE CLINICAL AND HISTOLOGICAL FEATURES.Timepoint: 1st year 15 TO 20 cases 2nd year 15 TO 20 cases—

Countries

India

Contacts

Public Contactsourabha patro

post graduate institute of medical education and research

sourabhlipi@gmail.com8872401912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026